Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA

被引：0
|
作者：
D Călugăru
M Călugăru
机构：
[1] University of Medicine,Department of Ophthalmology
来源：
Eye | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1113 / 1113
相关论文
共 50 条
  • [41] Anti-Vascular Endothelial Growth Factor Treatment Patterns and Outcomes in Retinal Vein Occlusion in Routine Clinical Practice
    Xu, Colin M.
    Kim, Erin
    Valentim, Carolina C. S.
    Seth, Kanika
    Muste, Justin C.
    Perkins, Scott
    Singh, Rishi P.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2022, 53 (11) : 626 - +
  • [42] Anti-Vascular Endothelial Growth Factor Treatment Patterns and Outcomes in Retinal Vein Occlusion in Routine Clinical Practice
    Xu, Colin
    Kim, Erin
    Valentim, Carolina Carvalho Soares
    Seth, Kanika
    Muste, Justin
    Singh, Rishi P.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [43] Ranibizumab and aflibercept intravitreal injection for treatment naive and refractory macular oedema in branch retinal vein occlusion
    Hogg, H. D. Jeffry
    Di Simplicio, Sandro
    Pearce, Mark S.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2021, 31 (02) : 548 - 555
  • [44] Clinical evaluation of ranibizumab and conbercept for the treatment of macular edema secondary to central retinal-vein occlusion
    Ye, Ya
    Huang, Zhen
    Yan, Ming
    Yu, Juan
    ASIAN JOURNAL OF SURGERY, 2024, 47 (06) : 2963 - 2964
  • [45] Ranibizumab tachyphylaxis in a case of macular edema related to central retinal vein occlusion: Lasting effectiveness of switching to aflibercept
    Gambrelle, J.
    Robinet, A.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2017, 40 (03): : E83 - E84
  • [46] Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in Central Retinal Vein Occlusion (CRVO): 1 year results
    Pfau, Maximilian
    Fassnacht-Riederle, Heidi
    Becker, Matthias
    Michels, Stephan
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [47] Sir, Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
    Nghiem-Buffet, S.
    Baillif, S.
    Regnier, S.
    Skelly, A.
    Yu, N.
    Sodi, A.
    EYE, 2017, 31 (07) : 1113 - 1114
  • [48] Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
    Pennington, Becky
    Alshreef, Abualbishr
    Flight, Laura
    Metry, Andrew
    Poku, Edith
    Hykin, Philip
    Sivaprasad, Sobha
    Prevost, A. Toby
    Vasconcelos, Joana C.
    Murphy, Caroline
    Kelly, Joanna
    Yang, Yit
    Lotery, Andrew
    Williams, Michael
    Brazier, John
    PHARMACOECONOMICS, 2021, 39 (08) : 913 - 927
  • [49] Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
    Becky Pennington
    Abualbishr Alshreef
    Laura Flight
    Andrew Metry
    Edith Poku
    Philip Hykin
    Sobha Sivaprasad
    A. Toby Prevost
    Joana C. Vasconcelos
    Caroline Murphy
    Joanna Kelly
    Yit Yang
    Andrew Lotery
    Michael Williams
    John Brazier
    PharmacoEconomics, 2021, 39 : 913 - 927
  • [50] Incremental Cost-Utility Ratio of Intravitreal Aflibercept Compared with Ranibizumab for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion
    Cruess, Alan F.
    Jeddi, Mark
    Goeree, Ron
    Blackhouse, Gord
    Eriksson, Marianne
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
12345